The Dry AMD market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Dry AMD: An Overview
Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. Clinically, AMD is classified according to different approaches. One such approach is that the disease is classified as an early-stage to late-stage (advanced AMD). The advanced AMD is classified into the nonexudative or atrophic form (dry AMD) and the exudative or neovascular form (wet AMD).
The diagnostic methods of AMD include fundus imaging, fluorescein angiogenesis (FA), indocyanine green angiography (ICGA), optical coherence tomography (OCT), Optical coherence tomography angiography (OCTA), and artificial intelligence (AI). These techniques play an important role in the diagnosis of AMD and have their unique advantages.
Get the PDF Sample of the Report: Dry AMD Market Analysis
Dry AMD Market Key Facts
-
As per Prevent Blindness, age-related macular degeneration, affects an estimated 1.8 million Americans aged 40 years and older and an additional 7.3 million with large drusen are at substantial risk of developing AMD.
-
According to Gregory et al. (2006), dry AMD develops in ~85% of all patients with AMD. It is more common but less severe than Wet AMD.
-
According to the research report published by the European Society of Retina Specialists named Retinal disease in Europe, France accounted for the highest pooled prevalence estimate of late AMD 3.3%, closely followed by Italy 3.2%, Germany 2.4%, and Spain 2.3%.
-
According to a Japanese study by Sakurada et al. (2016), the prevalence of GA was 6.6% among elderly Japanese with AMD.
Key Benefits of Dry AMD Market Report
-
The report provides an in-depth analysis of Dry AMD Market Size and Share till 2032 in the seven major markets.
-
The report will help in developing business strategies by understanding the Dry AMD Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.
-
It covers Dry AMD current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.
-
The report provides a detailed assessment of the Dry AMD market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Dry AMD market size and share by analyzing the impact of current and emerging therapies on the market. It also provides a detailed assessment of the unmet needs, market drivers barriers, and emerging technologies.
The report gives a thorough detail of the Dry AMD Market Trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Dry AMD Epidemiology
The epidemiology section covers insights about the historical and current Dry AMD patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Dry AMD Epidemiology Subtype Segmentation
-
Total Prevalent cases of Age-related Macular Degeneration
-
Type-specific (Dry-AMD, Wet-AMD) Prevalence of Age-related Macular Degeneration
-
Stage-specific Prevalence of Dry Age-related Macular Degeneration
-
Age-specific Prevalence of Dry Age-related Macular Degeneration
-
Diagnosed and Treatable cases of Dry Age-related Macular Degeneration
Dry AMD Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dry AMD market or expected to get launched in the market during the study period. The analysis covers Dry AMD market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Dry AMD Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Dry AMD Therapeutics Analysis
A detailed understanding of the molecular mechanisms underlying wet AMD has led to several robust FDA-approved therapies. In contrast, there are not any approved treatments for dry AMD. The management of dry AMD consists of observation, regular follow-up evaluations, and documentation for timely recognition of visual function deterioration with appropriate rehabilitation and early CNV detection.
Some of the key companies in the Dry AMD Market include:
-
Gemini Therapeutics
-
Allegro Ophthalmics
-
Gyroscope Therapeutics
-
Alkeus Pharmaceuticals
-
IVERIC bio
-
Luxa Biotechnology
-
Regenerative Patch Technologies
-
OliX Pharmaceuticals
-
Apellis Pharmaceuticals
-
Ionis Pharmaceuticals
-
NGM Biopharmaceuticals
-
Eyestem
-
CellCure Neurosciences
-
Lin BioSciences
-
Iveric Bio
-
Stealth BioTherapeutics
-
Gensight Biologics
And many others
Dry AMD Therapies covered in the report includes:
-
Eyecyte RPE
-
OLX301A
-
CPCB-RPE1
-
RPESC RPE 4W
-
Zimura
-
ALK-001
-
GT005
-
Risuteganib
-
GEM103
And many more
Get More Detailed Insights into the Emerging Therapies & Key Companies: https://www.delveinsight.com/sample-request/dry-amd-market
Table of Content
1. Key Insights
2. Executive Summary
3. Dry AMD Competitive Intelligence Analysis
4. Dry AMD Market Overview at a Glance
5. Dry AMD Disease Background and Overview
6. Dry AMD Patient Journey
7. Dry AMD Epidemiology and Patient Population
8. Dry AMD Treatment Algorithm, Current Treatment, and Medical Practices
9. Dry AMD Unmet Needs
10. Key Endpoints of Dry AMD Treatment
11. Dry AMD Marketed Products
12. Dry AMD Emerging Therapies
13. Dry AMD Seven Major Market Analysis
14. Attribute Analysis
15. Dry AMD Market Outlook (7 major markets)
16. Dry AMD Access and Reimbursement Overview
17. KOL Views on the Dry AMD Market.
18. Dry AMD Market Drivers
19. Dry AMD Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/dry-amd-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
